Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Advanced Solid Tumor 130Advanced Solid Tumors 122Solid Tumor 101Mesothelioma, Malignant 48Solid Tumors 43Mesothelioma 42Hematopoietic and Lymphatic System Neoplasm 30Solid Tumor, Adult 27Retinoblastoma 20Pancreatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Lung Neoplasms 13Neoplasms 11Advanced Malignant Solid Tumor 11Advanced or Metastatic Solid Tumors 10Solid Tumors, Adult 9Sarcoma 9Hematopoietic and Lymphoid System Neoplasm 9Advanced Malignant Solid Tumors 9Stomach Neoplasms 8Solid Tumor Malignancies 8Neoplasm Metastasis 8Melanoma 8Malignant Solid Tumors 8Malignant Solid Neoplasm 8Locally Advanced or Metastatic Solid Tumors 8Kidney Neoplasms 8Colorectal Neoplasms 8Advanced/Metastatic Solid Tumors 8

Interventions

Immune Checkpoint Inhibitors 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immune-related Adverse Event × Other solid neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡